CompletedPhase 2NCT04003974
Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)
Studying Facioscapulohumeral dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fulcrum Therapeutics
- Principal Investigator
- Michelle Mellion, MDFulcrum Therapeutics
- Intervention
- Losmapimod oral tablet(drug)
- Enrollment
- 80 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2019 – 2021
Study locations (17)
- University of California Irvine, Irvine, California, United States
- University of California Los Angeles (UCLA), Los Angeles, California, United States
- University of Florida, Gainesville, Florida, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Kennedy Krieger Institute, Baltimore, Maryland, United States
- University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- University of Rochester Medical Center, Rochester, New York, United States
- Ohio State University, Columbus, Ohio, United States
- University of Utah, Salt Lake City, Utah, United States
- Virginia Commonwealth University, Richmond, Virginia, United States
- University of Washinton Medical Center, Seattle, Washington, United States
- Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
- Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada
- CHU de NICE- CHU pasteur2, Nice, France
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04003974 on ClinicalTrials.govOther trials for Facioscapulohumeral dystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07086521Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)Restem, LLC.
- RECRUITINGPHASE3NCT07038200A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHDAvidity Biosciences, Inc.
- RECRUITINGPHASE1, PHASE2NCT06907875A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular DystrophyEpicrispr Biotechnologies, Inc.
- ENROLLING BY INVITATIONNCT07164937Imaging and Gait Analysis in FSHD PatientsFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGNCT06911190Ten Year Follow-up in FSHD: the FOCUS 3 StudyRadboud University Medical Center
- RECRUITINGNCT07409142BetterLife FSHD: A Patient-driven Health and Research PlatformFSHD Society
- ENROLLING BY INVITATIONPHASE2NCT06547216Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)Avidity Biosciences, Inc.
- RECRUITINGNANCT06600308Walking ANalysis Interest in Persons wiTh facioscapulohumEral Muscular DystrophiesCentre Hospitalier Universitaire Dijon